Jefferies Group LLC reissued their buy rating on shares of Medtronic PLC (NYSE:MDT) in a research note published on Thursday. They currently have a $96.00 target price on the medical technology company’s stock.

A number of other equities analysts have also issued reports on MDT. BidaskClub raised shares of Medtronic PLC from a sell rating to a hold rating in a research report on Friday, August 11th. Zacks Investment Research lowered shares of Medtronic PLC from a hold rating to a sell rating in a research report on Monday, July 31st. UBS AG reissued an overweight rating on shares of Medtronic PLC in a research report on Thursday, August 24th. Oppenheimer Holdings, Inc. reissued a buy rating and set a $92.00 price target on shares of Medtronic PLC in a research report on Tuesday, August 22nd. Finally, Royal Bank Of Canada reissued a buy rating and set a $90.00 price target on shares of Medtronic PLC in a research report on Monday, August 21st. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and thirteen have issued a buy rating to the company. The company has an average rating of Hold and an average target price of $88.78.

Medtronic PLC (NYSE MDT) opened at 77.77 on Thursday. Medtronic PLC has a 12-month low of $69.35 and a 12-month high of $89.72. The stock’s 50 day moving average is $82.04 and its 200 day moving average is $83.67. The stock has a market capitalization of $105.35 billion, a PE ratio of 26.18 and a beta of 1.03.

Medtronic PLC (NYSE:MDT) last announced its quarterly earnings data on Tuesday, August 22nd. The medical technology company reported $1.12 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.08 by $0.04. Medtronic PLC had a net margin of 13.75% and a return on equity of 12.92%. The firm had revenue of $7.39 billion during the quarter, compared to analyst estimates of $7.44 billion. During the same period last year, the firm posted $1.03 EPS. Medtronic PLC’s revenue was up 3.1% on a year-over-year basis. Equities analysts anticipate that Medtronic PLC will post $4.77 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This story was originally published by Watch List News and is owned by of Watch List News. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://www.watchlistnews.com/jefferies-group-llc-reaffirms-buy-rating-for-medtronic-plc-mdt/1600906.html.

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 20th. Shareholders of record on Friday, September 29th will be paid a dividend of $0.46 per share. The ex-dividend date of this dividend is Thursday, September 28th. This represents a $1.84 annualized dividend and a yield of 2.37%. Medtronic PLC’s dividend payout ratio (DPR) is presently 61.95%.

In other Medtronic PLC news, CEO Omar Ishrak sold 140,407 shares of Medtronic PLC stock in a transaction on Friday, September 15th. The shares were sold at an average price of $81.63, for a total transaction of $11,461,423.41. Following the sale, the chief executive officer now owns 668,503 shares of the company’s stock, valued at approximately $54,569,899.89. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Bryan C. Hanson sold 12,000 shares of Medtronic PLC stock in a transaction on Monday, July 17th. The stock was sold at an average price of $88.57, for a total transaction of $1,062,840.00. The disclosure for this sale can be found here. Insiders own 0.31% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Jackson Grant Investment Advisers Inc. raised its holdings in shares of Medtronic PLC by 0.3% during the 1st quarter. Jackson Grant Investment Advisers Inc. now owns 2,920 shares of the medical technology company’s stock worth $235,000 after acquiring an additional 9 shares during the period. Hudock Capital Group LLC raised its holdings in shares of Medtronic PLC by 0.5% during the 2nd quarter. Hudock Capital Group LLC now owns 2,195 shares of the medical technology company’s stock worth $194,000 after acquiring an additional 11 shares during the period. Bollard Group LLC raised its holdings in shares of Medtronic PLC by 0.4% during the 2nd quarter. Bollard Group LLC now owns 3,651 shares of the medical technology company’s stock worth $324,000 after acquiring an additional 14 shares during the period. Triangle Securities Wealth Management raised its holdings in shares of Medtronic PLC by 0.3% during the 2nd quarter. Triangle Securities Wealth Management now owns 4,396 shares of the medical technology company’s stock worth $390,000 after acquiring an additional 15 shares during the period. Finally, IFC Holdings Incorporated FL raised its holdings in shares of Medtronic PLC by 0.3% during the 2nd quarter. IFC Holdings Incorporated FL now owns 5,673 shares of the medical technology company’s stock worth $501,000 after acquiring an additional 17 shares during the period. Institutional investors and hedge funds own 80.63% of the company’s stock.

Medtronic PLC Company Profile

Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.

Analyst Recommendations for Medtronic PLC (NYSE:MDT)

Receive News & Ratings for Medtronic PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.